WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018048939) METHODS OF TREATING OR PREVENTING ZIKA VIRUS INFECTION
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/048939    International Application No.:    PCT/US2017/050327
Publication Date: 15.03.2018 International Filing Date: 06.09.2017
IPC:
A61K 39/395 (2006.01), A61K 39/42 (2006.01), C07K 16/10 (2006.01), A61K 39/00 (2006.01)
Applicants: DANA-FARBER CANCER INSTITUTE, INC. [US/US]; 450 Brookline Avenue Boston, Massachusetts 02215-5450 (US)
Inventors: MARASCO, Wayne; (US)
Agent: ELRIFI, Ivor; (US).
KOZAKIEWICZ, Cynthia; (US)
Priority Data:
62/383,668 06.09.2016 US
Title (EN) METHODS OF TREATING OR PREVENTING ZIKA VIRUS INFECTION
(FR) PROCÉDÉS DE TRAITEMENT OU DE PRÉVENTION D’UNE INFECTION PAR LE VIRUS ZIKA
Abstract: front page image
(EN)The present invention provides antibodies that neutralize flavivirus and methods of use thereof. These antibodies are derived from mAb-1 1 which recognizes West Nile virus E protein and is cross-reactive with members of the flavivirus family, including dengue virus. The antibodies of the present invention prevent antibody-dependent enhancement of a viral infection by having a modified Fc region that does not bind to the Fey receptor. The invented antibody is used to treat flaviviral infections and symptoms thereof.
(FR)La présente invention concerne des anticorps qui neutralisent un flavivirus et des procédés d’utilisation de ceux-ci. Ces anticorps sont dérivés de mAb-1 1, qui reconnaît la protéine E du virus du Nil occidental et présente une réaction croisée avec des membres de la famille des flavivirus, comprenant le virus de la dengue. Les anticorps de la présente invention inhibent l’amplification dépendant des anticorps d’une infection virale car ils comportent une région Fc modifiée qui ne se lie pas au récepteur Fey. L’anticorps selon l’invention est utilisé pour traiter les infections flavivirales et les symptômes de celles-ci.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)